Search clinical trials for: Sorafenib Tablets

Total 7358 results

Fudan University

Terminated

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Leiden University Medical Center

Completed

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Thyroid Cancer

Netherlands
University of Pennsylvania

Completed

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Metastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid Cancer

United States
Vaxart

Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Norovirus Gastroenteritis

United States
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. (ALLAY-LID-I)

Parkinson's Disease | Levodopa Induced Dyskinesias (LID)

France, Spain, Germany, Canada, United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
Bayer

Completed

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (SORINT)

Carcinoma, Hepatocellular

Germany
Bayer

Completed

Regulatory Post Marketing Surveillance Study on Nexavar®

Carcinoma, Renal Cell | Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Bayer

Completed

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Belgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
Bayer

Terminated

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Carcinoma, Renal Cell

United States
Bayer

Completed

INSIGHT - Post Marketing Surveillance (INSIGHT)

Carcinoma, Hepatocellular

Germany, Austria
Bayer

Completed

Sorafenib Gastric Cancer Asian Phase I Study

Gastric Cancer

Japan
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
University of Wisconsin, Madison
Bayer

Completed

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Carcinoma, Non Small Cell Lung

United States
Bayer

Completed

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (SUCCESS)

Carcinoma, Hepatocellular

China
Bayer

Completed

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting (NEXST)

Carcinoma, Renal Cell

Poland
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (SARAH)

Liver Carcinoma

France
Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

Hepatocellular Carcinoma

Taiwan, Hong Kong, China, Thailand, Korea, Republic of, Singapore, Japan
Bayer

Completed

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Canada
Bayer
Amgen

Completed

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Cancer | Carcinoma, Non-Small Cell Lung

United States, Germany
Chinese Society of Lung Cancer

Completed

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Non-Small Cell Lung Cancer

China
Medical Research Council

Completed

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Kidney Cancer

United Kingdom
Bayer

Completed

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Poland, China, Slovakia, France, Germany, Indonesia, Korea, Republic of, Sweden, Philippines, Austria, Colombia, Czech Republic, Mexico, Russian Federation, Slovenia, Argentina, Greece, Netherlands
Istituto Clinico Humanitas

Completed

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Sarcoma, Soft Tissue

Italy
Bayer

Active, not recruiting

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (JPMS-DTC)

Thyroid Carcinoma

Japan
Bayer
ICON Clinical Research

Completed

Sorafenib Long Term Extension Program (STEP)

Neoplasms

Spain, Hong Kong, Canada, Germany, France, United States, United Kingdom, Taiwan, New Zealand, Australia, Belgium, China, Bulgaria, Italy, Colombia, Poland, Korea, Republic of, Brazil, Ukraine
Memorial Sloan Kettering Cancer Center
Mayo Clinic; Washington University School of Medicine; Astellas Pharma US, Inc.; University of Southern California and other collaborators

Completed

Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

United States
Bayer

Completed

Sorafenib for Residue Disease After Resection With Curative Intent (SECURE)

Carcinoma, Hepatocellular

China
Bayer

Completed

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Thyroid Carcinoma

Japan
Bayer

Completed

Sorafenib Dose Escalation in Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, France, Germany, United Kingdom, Poland
German Breast Group
Bayer

Completed

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer (SOFIA)

Breast Cancer

Germany
Bayer

Completed

BAY43-9006 Phase II Study for Renal Cell Carcinoma

Carcinoma, Renal Cell

Japan
Bayer

Completed

Extension Program for Bay 43-9006

Metastasis | Neoplasm

Canada, Belgium, Germany, United States
Bayer

Completed

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Neoplasms

United States
National Cancer Institute (NCI)

Completed

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

Sarcoma

United States
Bayer

Completed

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

China, Taiwan
Bayer

Completed

Long-term Extension From RCC Phase II (11515)

Carcinoma, Renal Cell

Japan
Bayer

Completed

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Belgium
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Liver Cancer

United States
Swedish Medical Center
Bayer; Amgen

Completed

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Lung Cancer

United States
Bayer

Completed

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Kidney Diseases
Tonix Pharmaceuticals, Inc.

Terminated

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Centre of Clinical Pharmacology, Hanoi Medical...

Not yet recruiting

Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome With Diarrhea

Vietnam
Institute of Liver and Biliary Sciences, India

Completed

Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

India
National Cancer Institute (NCI)

Completed

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Advanced Malignant Neoplasm

United States
Overseas Pharmaceuticals, Ltd.
Virginia Contract Research Organization Co., Ltd.

Terminated

To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers

Pain Control

Taiwan

Search clinical trials for: Sorafenib Tablets

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations